Delving into the Latest Updates on INP-102 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Insulin, POD insulin

Target

INSR

Mechanism

INSR agonists(Insulin receptor agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Alzheimer Disease

Inactive Indication-

Originator Organization

Ipi Legacy Liquidation Co.

Active Organization

Ipi Legacy Liquidation Co.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).

Start Date01 May 2025

Sponsor / Collaborator

Wake Forest School of Medicine

NCT06017726 / Not yet recruitingNot ApplicableIIT

Insulin Resistance in Non-diabetic Multiple Sclerosis Patients: Prevalence, Pre and Post-treatment Effect on Clinical, Cognitive Profile, Laboratory, and Radiological Markers

The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt
The main questions it aims to answer are:
1. what is the prevalence of insult resistance among Egyptian patients with Multiple sclerosis?
2. what are the effects of insulin resistance on multiple sclerosis disease activity and progression
3. what are the effects of treating insulin resistance on multiple sclerosis disease activity and progression participants with MS will be tested for IR to determine its prevalence, in the 2nd phase a group of MS patients with IR will be compared with another control group of MS patients without IR for clinical, laboratory, and radiological markers of disease activity and progression twice at baseline and after 1 year. in the 3rd phase, patients with IR will be divided into 2 groups one who will receive appropriate treatment for IR and the other group without treatment of IR and will be compared by the end of the 2nd year for clinical, laboratory and radiological markers of disease activity and progression

Start Date01 Dec 2024

Sponsor / Collaborator

Assiut University

IRCT20240606062025N1 / RecruitingPhase 3IIT

Investigating the effect of administration of insulin glucose solution in the preanhepatic phase on the heart outcome of patients undergoing orthotopic liver transplantation

Start Date19 Jun 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

100 Clinical Results associated with INP-102

Login to view more data

100 Translational Medicine associated with INP-102

Login to view more data

100 Patents (Medical) associated with INP-102

Login to view more data

5

Literatures (Medical) associated with INP-102

01 Aug 2024·Journal of Hazardous Materials

Peroxidase in plant defense: Novel insights for cadmium accumulation in rice (Oryza sativa L.)

Article

Author: Wu, Yingjie ; Liu, Jiahui ; Tao, Qi ; Lv, Yunxuan ; Wang, Changquan ; Li, Bing ; Li, Meng

Phenylpropanoid biosynthesis plays crucial roles in the adaptation to cadmium (Cd) stress. Nevertheless, few reports have dabbled in physiological mechanisms of such super pathway regulating Cd accumulation in plants. Herein, by integrating transcriptomic, histological and molecular biology approaches, the present study dedicated to clarify molecular mechanism on how rice adapt to Cd stress via phenylpropanoid biosynthesis. Our analysis identified that the enhancement of phenylpropanoid biosynthesis was as a key response to Cd stress. Intriguingly, POD occupied a significant part in this process, with the number of POD related genes accounted for 26/29 of all upregulated genes in phenylpropanoid biosynthesis. We further used SHAM (salicylhydroxamic acid, the POD inhibitor) to validate that POD exhibited a negative correlation with the Cd accumulation in rice tissues, and proposed two intrinsic molecular mechanisms on POD in contributing to Cd detoxification. One strategy was that POD promoted the formation of lignin and CSs both in endodermis and exodermis for intercepting Cd influx. In detail, inhibited POD induced by external addition of SHAM decreased the content of lignin by 50.98-66.65 % and delayed percentage of the D_TIP-CS to root length by 39.17-104.51 %. The other strategy was expression of transporter genes involved in Cd uptake, including OsIRT1, OsIRT2, OsZIP1 and OsZIP, negatively regulated by POD. In a word, our findings firstly draws a direct link between POD activity and the Cd accumulation, which is imperative for the breeding of rice with low-Cd-accumulating capacity in the future.

01 May 2019·Journal of Chromatography BQ3 · MEDICINE

Purification of peroxidase enzyme from radish species in fast and high yield with affinity chromatography technique

Q3 · MEDICINE

Article

Author: Erel, Deniz ; Sengül, Mehmet Emin ; Almaz, Zuleyha ; Oztekin, Aykut ; Gerni, Serpil ; Kocak, Seyma Mehtap ; Ozdemir, Hasan

In this study, an effective single step affinity method is presented for purifying plant peroxidase (POD) enzymes from radish species. This method make possible to purify the enzymes in high yield and purity. Briefly, 10 different 4-amino benzohydrazide derivatives were synthesized and identified as new competitive POD inhibitors. Then, these derivatives were coupled to Sepharose 4B-L-Tyrosine support matrix by diazotization to form the affinity gels. Purification factors were recorded as 54.8% yield - 665-fold, 33.8% yield - 613-fold, 22.7% yield - 595-fold, 34.4% yield - 781-fold, 40.9% yield - 282-fold for turnip (T-POD), black radish (BR-POD), daikon (D-POD), sweet radish (SR-POD) and kohlrabi radish, (KR-POD), respectively. It has also been shown that the affinity gels, which prepared using the 4-amino 3-bromo benzohydrazide and 4-amino 2-nitro benzohydrazide molecules, capable to purify all radish species POD enzymes in high purity and yield.

01 Nov 2017·Plant Physiology and BiochemistryQ2 · BIOLOGY

Overexpressing sweetpotato peroxidase gene swpa4 affects nitric oxide production by activating the expression of reactive oxygen species- and nitric oxide-related genes in tobacco

Q2 · BIOLOGY

Article

Author: Yun, Byung-Wook ; Kim, Yun-Hee ; Kwak, Sang-Soo ; Park, Sung Chul

Reactive oxygen species (ROS) and nitric oxide (NO) are key signaling molecules involved in various developmental and stress responses in plants. NO and ROS production, which is triggered by various stimuli, activates downstream signaling pathways to help plants cope with abiotic and biotic stresses. Recent evidence suggests that the interplay between NO and ROS signaling plays a critical role in regulating stress responses. However, the underlying molecular mechanism remains poorly understood. We previously reported that transgenic tobacco overexpressing the swpa4 peroxidase (POD) gene from sweetpotato exhibits increased tolerance to stress. Overexpression of swpa4 also induces the generation of H₂O₂ and activates the expression of various extracellular acidic pathogenesis-related (PR) genes. Here, we show that swpa4 positively regulates the expression of ROS- and NO-related genes in transgenic tobacco plants. Plants expressing swpa4 exhibited increased expression of ROS-related genes and increased ROS-related enzyme activity under normal conditions and H₂O₂ treatment, whereas the expression of NO associated 1 (NOA1) only increased under normal conditions. Moreover, plants overexpressing swpa4 showed increased NO levels under normal conditions and after treatment with the NO donor sodium nitroprusside (SNP). Interestingly, treatment with a POD inhibitor dramatically reduced NO levels in swpa4 transgenic plants. These findings suggest that swpa4 regulates H₂O₂ and NO homeostasis in plants under stress conditions, thereby establishing a possible molecular link between the NO and ROS signaling pathways.

100 Deals associated with INP-102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	-	Ipi Legacy Liquidation Co.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2023	Not Applicable	Diabetes Mellitus, Type 2	-	Semaglutide	(hjywnpjvcq) = prblmzzifl eyzlzwfolh (jfrqykyvsa )	-	05 Oct 2023
				Insulin	cegoklzdrg(jtdnnsuskm) = bavjvkzkpr hqylkvfsyu (fqcmpsbljp ) View more
Omnipod 5 (EASD2023)	Not Applicable	Diabetes Mellitus, Type 1	-	Omnipod 5 Automated Insulin Delivery (AID) system	(oobupdhsrd) = uytxkvgsqn ybrkcxbjzr (eswqukjbgb ) View more	Positive	05 Oct 2023
EASD2022	Not Applicable	Diabetes Mellitus, Type 2	814	iGlarLixi (insulin glargine 100 U/mL + lixisenatide)	ltqdtcnaod(eborieypdi) = dkpvsndstn jrlhnfqnkg (osmaueqhzz, <0.025)	Positive	20 Sep 2022
				Basal insulin (BI) + Rapid-acting insulin (RAI)	ltqdtcnaod(eborieypdi) = qksydcddfz jrlhnfqnkg (osmaueqhzz, <0.025)
NCT01963728 (CTgov)	Phase 4	Diabetes Mellitus	2	Insulin, Isophane (Insulin Isophane)	yiiosknbuq(wsbpbxrgoa) = hhhkonpsqb ejfekulppf (hhhllfwbnn, ehbrbztruy - jkskesdmtm) View more	-	12 Jan 2022
				Insulin Glargine (Insulin Glargine)	yiiosknbuq(wsbpbxrgoa) = whohayphme ejfekulppf (hhhllfwbnn, ahaqwuoncc - xhmqrrswbp) View more
EASD2021	Not Applicable	Diabetes Mellitus, Type 1	-	Omnipod DASH ® Insulin Management System	yuqtltrjxx(zznrcmvvjx) = tftuxegasw sydimnreli (eewkbgbiom ) View more	-	30 Sep 2021
				Omnipod DASH ® Insulin Management System	yuqtltrjxx(zznrcmvvjx) = vvkpytqxxi sydimnreli (eewkbgbiom ) View more
EASD2021	Not Applicable	Diabetes Mellitus, Type 1	-	Omnipod DASH® Insulin Management System	sqtceyaguh(wpbbpxsmof) = ksetyoljrz kqmpbvklhj (uiwtwkkbrv, 2.7) View more	-	30 Sep 2021
Accu-Chek DiaPort (EASD2021)	Not Applicable	Diabetes Mellitus	49	Continuous intraperitoneal insulin infusion (CIPII) with Accu-Chek DiaPort system	(dhtvlkcbwo) = rvdbgozgfw srqvbizfff (utefzzbdzq )	Positive	29 Sep 2021
EASD2020	Not Applicable	Diabetes Mellitus, Type 2	-	Basal-bolus insulin	(allgvwhqae) = rnncqaojzb hdtzlxecmv (hxjybjakys, 4.3) View more	Positive	22 Sep 2020
				Premixed insulin	(allgvwhqae) = bkvqvopecc hdtzlxecmv (hxjybjakys, 4.2) View more
NCT03013985 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	247	Glargine U300+Glulisine Insulin (Basal Bolus Insulin With Glargine U300 and Glulisine Insulin)	cfylyklxtj(dzmdjyydpt) = ncwdvdqacw uueriflkah (mlyuvuxmjm, wqvgdydexs - lrbpqgnkgc) View more	-	07 May 2020
				Glargine U100+Glulisine Insulin (Basal Bolus Insulin With Glargine U100 and Glulisine Insulin)	cfylyklxtj(dzmdjyydpt) = oxdvgrtwup uueriflkah (mlyuvuxmjm, pfnymxpfdx - ztqaghfuim) View more
BOX family study (EASD2019)	Not Applicable	Diabetes Mellitus insulin autoantibodies	4,752	Luciferase-tagged (pro)insulin constructs	amibzfblqd(kydsqgkfaa) = tykncoktpu rqsifanyqv (scrlgsqfzs )	Positive	17 Sep 2019
				Luciferase-tagged (pro)insulin constructs	amibzfblqd(kydsqgkfaa) = zogwqgnvlm rqsifanyqv (scrlgsqfzs )